{
    "clinical_study": {
        "@rank": "154528", 
        "arm_group": {
            "arm_group_label": "rectal cancer with stage II-IV", 
            "description": "rectal cancer with stage II-IV intervention: pelvic radiotherapy (45-55Gy) concurrent chemotherapy using capecitabine and oxaliplatin"
        }, 
        "biospec_descr": {
            "textblock": "whole blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Rectal cancer is one of the most common malignant tumors in the world. However, there's also\n      no reliable and sensitive method to monitor diseases and evaluate therapy responses till\n      now. Circulating tumor cells, which could reflect tumor's status correctly and reliably, may\n      be a promising method in this field. This study is to investigate the role of circulating\n      tumor cells in evaluating and predicting the responses of chemoradiotherapy in rectal\n      cancer."
        }, 
        "brief_title": "Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Rectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Rectal Neoplasms", 
                "Neoplastic Cells, Circulating"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically verified rectal carcinoma\n\n          -  Locally advanced tumor (cT3-4 and/or N+ by transrectal ultrasound and/or pelvic\n             magnetic resonance imaging)\n\n          -  the distance from anal verge <= 12cm\n\n          -  with or without metastasis\n\n          -  Age 18-75 years old\n\n          -  ECOG PS 0-2\n\n          -  No previous chemotherapy or radiotherapy for rectal carcinoma\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  no histologically verified rectal carcinoma\n\n          -  rectal cancer with stage I\n\n          -  distance from verge >12cm\n\n          -  age <=18 or >=75 years old\n\n          -  performed previously chemotherapy or radiotherapy\n\n          -  infection diseases within three months\n\n          -  serious other diseases\n\n          -  no written informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "rectal cancer diagnosed with stage II-IV"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671891", 
            "org_study_id": "SCRC-NM-1001"
        }, 
        "intervention": [
            {
                "arm_group_label": "rectal cancer with stage II-IV", 
                "description": "45-55Gy", 
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "rectal cancer with stage II-IV", 
                "description": "radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)", 
                "intervention_name": "capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "rectal cancer", 
            "circulating tumor cells", 
            "predict responses"
        ], 
        "lastchanged_date": "August 21, 2012", 
        "link": [
            {
                "description": "circulating tumor cells in colorectal cancer", 
                "url": "http://www.ncbi.nlm.nih.gov/pubmed/22230943"
            }, 
            {
                "description": "Circulating tumors cells as biomarkers: progress toward biomarker qualification", 
                "url": "http://www.ncbi.nlm.nih.gov/pubmed/22157288"
            }
        ], 
        "location": {
            "contact": {
                "email": "ganjumedecin@hotmail.com", 
                "last_name": "Wenjie Sun, Master", 
                "phone": "86-21-64175590"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Shanghai Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Zhen Zhang, PhD,MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Wenjie Sun, Master,MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer", 
        "overall_contact": {
            "email": "ganjumedecin@hotmail.com", 
            "last_name": "Wenjie Sun, Master", 
            "phone": "86-21-64175590-1600"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_outcome": {
            "measure": "circulating tumor cells level changes after radiotherapy", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671891"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Zhen Zhang", 
            "investigator_title": "director of radiotherapy department in Fudan university shanghai cancer center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "disease-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "serum carcinoembryonic antigen (CEA) level", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "pathological response (tumor regression grade)if surgery", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "RECIST-based tumor response at 10 week after radiotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}